Olympus Corp
TSE:7733
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| JP |
|
Olympus Corp
TSE:7733
|
2.2T JPY |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
192.6B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
176.6B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
136.1B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
130.1B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
110.3B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
59.2B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
46.5B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
51.3B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44.6B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
40.1B USD |
Loading...
|
Market Distribution
| Min | -122 700% |
| 30th Percentile | 2.9% |
| Median | 5.4% |
| 70th Percentile | 8.5% |
| Max | 63 031.4% |
Other Profitability Ratios
Olympus Corp
Glance View
Olympus Corporation, originating from the heart of Japan in 1919, has evolved into a global powerhouse, particularly revered for its contributions to the field of optics and imaging. Initially carving its reputation through crafting precision microscope lenses, Olympus seamlessly expanded its capabilities into the realms of endoscopy and digital imaging. This strategic pivot not only defined its legacy but firmly anchored its presence in the medical world, where it became a leader in endoscopic technology. The company adeptly leveraged its expertise to revolutionize medical diagnostics and treatment, helping medical professionals see and diagnose better—enhancing both physician dexterity and patient outcomes. Revenue for Olympus is predominantly driven by its Medical Business sector, which constitutes a significant portion of its overall profits, underscoring its transformation from a diversified manufacturer to a specialized player in healthcare technology. They are deeply committed to R&D, funneling substantial resources to innovate and bolster their portfolio in medical devices, particularly in fields like therapeutic interventions. While imaging products for consumers have historically been a notable segment, the shift toward medical technology aligns with broader market demands and ensures sustainable growth. This focus demonstrates Olympus's intent to maximize its competitive advantages, allowing it to remain at the forefront of its niche industries and effectively respond to global healthcare challenges.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Olympus Corp is 10%, which is below its 3-year median of 17.8%.
Over the last 3 years, Olympus Corp’s Net Margin has decreased from 14.9% to 10%. During this period, it reached a low of 1.7% on Jun 30, 2024 and a high of 40% on Jun 30, 2023.